Wedbush Securities Inc Marker Therapeutics, Inc. Transaction History

Wedbush Securities Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	SELL	$0.24 - $4.58 $3,840 - $73,280	-16,000 Reduced 15.99%	84,068 $22,000
Q2 2022 Jul 21, 2022	BUY	$0.26 - $0.46 $2,600 - $4,600	10,000 Added 11.1%	100,068 $33,000
Q1 2022 Apr 19, 2022	BUY	$0.37 - $1.0 $10,175 - $27,500	27,500 Added 43.95%	90,068 $39,000
Q4 2021 Jan 13, 2022	SELL	$0.95 - $1.72 $7,125 - $12,900	-7,500 Reduced 10.7%	62,568 $59,000
Q4 2020 Feb 16, 2021	SELL	$1.36 - $1.75 $35,491 - $45,669	-26,097 Reduced 27.14%	70,068 $102,000
Q3 2020 Oct 20, 2020	SELL	$1.5 - $2.2 $21,013 - $30,819	-14,009 Reduced 12.72%	96,165 $144,000
Q2 2020 Jul 16, 2020	BUY	$1.69 - $2.79 $67,779 - $111,895	40,106 Added 57.24%	110,174 $228,000
Q1 2020 Apr 17, 2020	BUY	$1.59 - $3.35 $7,950 - $16,750	5,000 Added 7.68%	70,068 $133,000
Q4 2019 Jan 16, 2020	BUY	$2.68 - $4.85 $22,780 - $41,225	8,500 Added 15.03%	65,068 $187,000
Q3 2019 Oct 17, 2019	BUY	$4.1 - $9.0 $147,796 - $324,432	36,048 Added 175.67%	56,568 $289,000
Q2 2019 Aug 01, 2019	BUY	$5.15 - $7.92 $105,678 - $162,518	20,520 New	20,520 $163,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $269M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.